Arthur J. Kudla

1.5k total citations
27 papers, 1.2k citations indexed

About

Arthur J. Kudla is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Arthur J. Kudla has authored 27 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 13 papers in Molecular Biology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Arthur J. Kudla's work include HER2/EGFR in Cancer Research (12 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Multiple Myeloma Research and Treatments (5 papers). Arthur J. Kudla is often cited by papers focused on HER2/EGFR in Cancer Research (12 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Multiple Myeloma Research and Treatments (5 papers). Arthur J. Kudla collaborates with scholars based in United States, France and United Kingdom. Arthur J. Kudla's co-authors include Stephen F. Konieczny, Matthew J. Flick, Yanfeng Kong, Violette Paragas, Bradley B. Olwin, Ulrik B. Nielsen, Brian D. Harms, Neeraj Kohli, Birgit Schoeberl and Michael J. Feldhaus and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Arthur J. Kudla

27 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arthur J. Kudla United States 12 782 416 376 107 91 27 1.2k
Anthony O’Grady Ireland 22 527 0.7× 435 1.0× 178 0.5× 27 0.3× 232 2.5× 54 1.2k
Nora Vaisman Israel 12 930 1.2× 544 1.3× 337 0.9× 16 0.1× 103 1.1× 12 1.3k
Bradford W. Ozanne United Kingdom 20 1.1k 1.4× 537 1.3× 229 0.6× 72 0.7× 580 6.4× 28 1.8k
Chang‐Lung Lee United States 20 411 0.5× 276 0.7× 268 0.7× 66 0.6× 26 0.3× 42 1.0k
George D. Kamphaus United States 9 643 0.8× 155 0.4× 167 0.4× 32 0.3× 91 1.0× 11 1.2k
David F. Meoli United States 14 586 0.7× 110 0.3× 190 0.5× 306 2.9× 34 0.4× 19 1.1k
Liutao Du United States 16 832 1.1× 147 0.4× 140 0.4× 40 0.4× 32 0.4× 22 1.1k
Frank Herting Switzerland 13 318 0.4× 232 0.6× 196 0.5× 42 0.4× 38 0.4× 28 712
Yalai Bai United States 20 455 0.6× 426 1.0× 175 0.5× 35 0.3× 30 0.3× 37 1.1k
Lily Yen Canada 17 861 1.1× 639 1.5× 245 0.7× 11 0.1× 122 1.3× 18 1.3k

Countries citing papers authored by Arthur J. Kudla

Since Specialization
Citations

This map shows the geographic impact of Arthur J. Kudla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur J. Kudla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur J. Kudla more than expected).

Fields of papers citing papers by Arthur J. Kudla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arthur J. Kudla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur J. Kudla. The network helps show where Arthur J. Kudla may publish in the future.

Co-authorship network of co-authors of Arthur J. Kudla

This figure shows the co-authorship network connecting the top 25 collaborators of Arthur J. Kudla. A scholar is included among the top collaborators of Arthur J. Kudla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arthur J. Kudla. Arthur J. Kudla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sekeres, Mikkael A., Michael Schuster, Magalie Joris, et al.. (2022). A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes. Annals of Hematology. 101(8). 1689–1701. 11 indexed citations
3.
Grosicki, Sebastian, Ulf‐Henrik Mellqvist, Suzanne Trudel, et al.. (2022). Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort. Blood. 140(Supplement 1). 4407–4408. 24 indexed citations
4.
Zeidan, Amer M., Michael W. Schuster, Jürgen Krauter, et al.. (2019). Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia. Blood. 134(Supplement_1). 3916–3916. 10 indexed citations
5.
Sekeres, Mikkael A., Michael W. Schuster, Magalie Joris, et al.. (2019). A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia. Blood. 134(Supplement_1). 177–177. 16 indexed citations
6.
Finn, Gregory J., Arthur J. Kudla, Victoria Rimkunas, et al.. (2017). Abstract A19: Identification of Heregulin (HRG) expression as a driver of a difficult-to-treat cancer phenotype and development of a companion diagnostic for the HRG-ErbB3 targeting drug seribantumab. Clinical Cancer Research. 23(1_Supplement). A19–A19. 1 indexed citations
7.
8.
Onsum, Matthew, Elena Geretti, Violette Paragas, et al.. (2013). Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients. American Journal Of Pathology. 183(5). 1446–1460. 72 indexed citations
9.
Lahdenranta, Johanna, Violette Paragas, Arthur J. Kudla, et al.. (2013). Preclinical activity of MM-111, a bispecific ErbB2/ErbB3 antibody in previously treated ErbB2-positive gastric and gastroesophageal junction cancer.. Journal of Clinical Oncology. 31(4_suppl). 48–48. 3 indexed citations
10.
Zhang, Bo, Johanna Lahdenranta, Jinyan Du, et al.. (2013). Abstract 4633: MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancer.. Cancer Research. 73(8_Supplement). 4633–4633. 9 indexed citations
11.
McDonagh, Charlotte F., Alexandra Huhalov, Brian D. Harms, et al.. (2012). Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3. Molecular Cancer Therapeutics. 11(3). 582–593. 222 indexed citations
12.
Zhang, Bo, Alexandra Huhalov, Olga Burenkova, et al.. (2011). Abstract 655: Combination of MM-111, an ErbB2/ErbB3 bispecific antibody, with endocrine therapies as an effective strategy for treatment of ER+/HER2+ breast cancer. Cancer Research. 71(8_Supplement). 655–655. 1 indexed citations
13.
14.
Schoeberl, Birgit, Emily A. Pace, Jonathan B. Fitzgerald, et al.. (2009). Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis. Science Signaling. 2(77). ra31–ra31. 275 indexed citations
15.
Mitin, Natalia, Arthur J. Kudla, Stephen F. Konieczny, & Elizabeth J. Taparowsky. (2001). Differential effects of Ras signaling through NFκB on skeletal myogenesis. Oncogene. 20(11). 1276–1286. 32 indexed citations
16.
Kudla, Arthur J., et al.. (1998). The FGF Receptor–1 Tyrosine Kinase Domain Regulates Myogenesis but Is Not Sufficient to Stimulate Proliferation. The Journal of Cell Biology. 142(1). 241–250. 33 indexed citations
17.
Kong, Yanfeng, Matthew J. Flick, Arthur J. Kudla, & Stephen F. Konieczny. (1997). Muscle LIM Protein Promotes Myogenesis by Enhancing the Activity of MyoD. Molecular and Cellular Biology. 17(8). 4750–4760. 234 indexed citations
18.
Patrie, Kevin M., Arthur J. Kudla, Bradley B. Olwin, & Ing‐Ming Chiu. (1995). Conservation of Ligand Specificity between the Mammalian and Amphibian Fibroblast Growth Factor Receptors. Journal of Biological Chemistry. 270(48). 29018–29024. 11 indexed citations
19.
Olwin, Bradley B., Kevin Hannon, & Arthur J. Kudla. (1994). Are fibroblast growth factors regulators of myogenesis in vivo?. PubMed. 5(2). 145–158. 38 indexed citations
20.
Olwin, Bradley B., Kevin Hannon, Patrick W. Hein, et al.. (1994). Role of FGFs in skeletal muscle and limb development. Molecular Reproduction and Development. 39(1). 90–101. 59 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anthony O’Grady Breakdown of academic impact, for papers by Nora Vaisman Breakdown of academic impact, for papers by Bradford W. Ozanne Breakdown of academic impact, for papers by Chang‐Lung Lee Breakdown of academic impact, for papers by George D. Kamphaus Breakdown of academic impact, for papers by David F. Meoli Breakdown of academic impact, for papers by Liutao Du Breakdown of academic impact, for papers by Frank Herting Breakdown of academic impact, for papers by Yalai Bai Breakdown of academic impact, for papers by Lily Yen
Rankless by CCL
2026